

Datasheet: TZA044 BATCH NUMBER 166857

Description:	HUMAN ANTI OCRELIZUMAB
Specificity:	OCRELIZUMAB
Other names:	Ocrevus
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD50641ad
Isotype:	Fab antibody
Quantity:	0.1 mg

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .						
		Yes	No	Not Determined	Suggested Dilution		
	ELISA	•					
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.						
Product Form	A monovalent human recombinant Fab (lambda light chain) selected from Bio-Rad's human antibody phage display libraries. The antibody is tagged with a DYKDDDDK tag, a SpyTag version 2 (VPTIVMVDAYKRYK) and a His6-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.						
Preparation	Metal chelate affinity chr	omatograp	hy				
Source	E.coli						
Buffer Solution	Phosphate buffered salir	ıe					
Preservative Stabilisers	0.0095% MIT						
Approx. Protein Concentrations	Antibody concentration ().5 mg/ml					

Immunogen	Ocrelizumab
Specificity	Human Anti-Ocrelizumab Antibody, clone AbD50641ad is a paratope specific, inhibitory, anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug ocrelizumab and its biosimilar products. Consequently, this antibody can be used to measure free ocrelizumab levels in serum from patients.
	This antibody is available in two formats - a monovalent Fab unconjugated format, clone AbD50641ad (TZA044), which has a SpyTag incorporated. This format can be used as a capture antibody in a pharmacokinetic (PK) bridging ELISA together with AbD50651 as a detection antibody. Clone AbD50641 is also available in full length IgG1 format under product code <u>HCA400</u> which can be used in an ADA bridging ELISA as a surrogate positive control.
	Human Anti-Ocrelizumab Antibody, clone AbD50641ad has been shown to cross-react with the antibody drug rituximab (tradename Rituxan). Ocrelizumab is the humanized form of rituximab. There are changes in at least one of the CDRs and it contains Fc modification.
	Ocrelizumab (trade name Ocrevus) is a monoclonal IgG1/kappa antibody (VH3/κ1). In vitro, it binds to CD20 cell surface molecules on target cells thereby inducing immune effector mechanisms such as antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. In vivo, ocrelizumab selectively and effectively depletes CD20 ⁺ B cells. Hence, it is an immunosuppressive drug. Ocrelizumab is used to treat primary progressive multiple sclerosis and relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).
Affinity	The monovalent intrinsic affinity of Human anti-Ocrelizumab Antibody, clone AbD50641ad was measured as K _D <0.001 nM by real time, label-free molecular interaction analysis on immobilized ocrelizumab.
ELISA	This product may be used in a direct ELISA. Clone AbD50641ad can be used as the capture antibody for ocrelizumab in a PK bridging ELISA together with clone AbD50651pap (<u>TZA045P</u>) as the detection antibody.
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
	Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See

	bio-rad.com/en-us/trademarks for details. His-tag is a registered trademark of EMD Biosciences. Ocrevus is a registered trademark of Genentech/ Roche and Biogen. Rituxan is a registered trademark of Genentech and Biogen.			
Health And Safety Information	Material Safety Datasheet documentation #20479 available at: https://www.bio-rad-antibodies.com/SDS/TZA044 20479			
Licensed Use	For <i>in vitro</i> . research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.			
Regulatory	For research purposes only			
Technical Advice	Recommended protocols for coupling a Fab antibody with a SpyTag to a SpyCatcher can be found at <u>SpyTag and SpyCatcher Products</u> , and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>			

Related Products

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A) SpyTag3 PEPTIDE (BLP086) HUMAN ANTI OCRELIZUMAB (HCA400) HUMAN ANTI OCRELIZUMAB (HCA401) HUMAN ANTI OCRELIZUMAB (TZA045) HUMAN ANTI OCRELIZUMAB:HRP (TZA045P) BiSpyCatcher2:HRP (TZC002P) HUMAN ANTI OCRELIZUMAB (HCA399)

North & South	Tel: +1 800 265 7376 Wo	orldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-rad.com		Email: antibody_sales_uk@bio-rad.com		Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M429200:240321'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint